SL
SVB Leerink Latest Price Targets & Analyst Ratings
| Stock | Analyst | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|---|
26
Ionis Pharmaceuticals
IONS
$9.76B
|
MF
Mani Foroohar
| $61.23 | $27 |
56%
downside
| Market Perform | 2 years ago |
|
27
Teladoc Health
TDOC
$1.38B
|
SD
Stephanie Davis
| $7.82 | $34 |
335%
upside
| Outperform | 2 years ago |
|
28
AbbVie
ABBV
$375B
|
DR
David Risinger
| $212.56 | $153 |
28%
downside
| Market Perform | 2 years ago |
|
29
Vertex Pharmaceuticals
VRTX
$102B
|
DR
David Risinger
| $396.12 | $365 |
8%
downside
| Outperform | 2 years ago |
|
30
Illumina
ILMN
$15.7B
|
PS
Puneet Souda
| $98.93 | $250 |
153%
upside
| Outperform | 2 years ago |
|
31
Premier
PINC
$2.13B
|
SD
Stephanie Davis
| $25.85 | $42 |
62%
upside
| Outperform | 2 years ago |
|
32
Cigna
CI
$81.5B
|
WM
Whit Mayo
| $305.31 | $335 |
10%
upside
| Market Perform | 2 years ago |
|
33
Immunovant
IMVT
$2.99B
|
TS
Thomas Smith
| $17.14 | $21 |
23%
upside
| Outperform | 2 years ago |
|
34
4D Molecular Therapeutics
FDMT
$340M
|
MF
Mani Foroohar
| $7.27 | $14 |
93%
upside
| Market Perform | 2 years ago |
|
35
Genmab
GMAB
$16.9B
| $27.54 | $36 |
31%
upside
| Market Perform | 2 years ago |
|
|
36
Gilead Sciences
GILD
$143B
|
DR
David Risinger
| $115.05 | $91 |
21%
downside
| Market Perform | 2 years ago |
|
37
Pharvaris
PHVS
$1.48B
|
JS
Joseph Schwartz
| $23.05 | $18 |
22%
downside
| Outperform | 2 years ago |
|
38
KalVista Pharmaceuticals
KALV
$796M
|
JS
Joseph Schwartz
| $15.82 | $20 |
26%
upside
| Outperform | 2 years ago |
|
39
Merck
MRK
$212B
|
DG
Daina Graybosch
| $84.71 | $122 |
44%
upside
| Outperform | 2 years ago |
|
|
40
Ionis Pharmaceuticals
IONS
$9.76B
|
JS
Joseph Schwartz
| $61.23 | $34 |
44%
downside
| Market Perform | 2 years ago |
|
41
BioMarin Pharmaceuticals
BMRN
$11.1B
|
JS
Joseph Schwartz
| $57.77 | $130 |
125%
upside
| Outperform | 2 years ago |
|
42
Bio-Techne
TECH
$8.46B
|
PS
Puneet Souda
| $54.41 | $110 |
102%
upside
| Outperform | 2 years ago |
|
43
Amgen
AMGN
$153B
|
DR
David Risinger
| $283.64 | $267 |
6%
downside
| Market Perform | 2 years ago |
|
44
Hologic
HOLX
$14.8B
|
PS
Puneet Souda
| $66.76 | $93 |
39%
upside
| Outperform | 2 years ago |
|
45
Pfizer
PFE
$141B
|
DR
David Risinger
| $24.88 | $48 |
93%
upside
| Market Perform | 2 years ago |
|
46
Denali Therapeutics
DNLI
$2.26B
|
MG
Marc Goodman
| $15.43 | $50 |
224%
upside
| Outperform | 2 years ago |
|
47
Xeris Biopharma Holdings
XERS
$1.27B
|
RR
Roanna Ruiz
| $7.85 | $5 |
36%
downside
| Outperform | 2 years ago |
|
48
Vir Biotechnology
VIR
$732M
|
RR
Roanna Ruiz
| $5.27 | $43 |
716%
upside
| Outperform | 2 years ago |
|
49
scPharmaceuticals
SCPH
$299M
|
RR
Roanna Ruiz
| $5.57 | $13 |
133%
upside
| Outperform | 2 years ago |
|
50
Atea Pharmaceuticals
AVIR
$267M
|
RR
Roanna Ruiz
| $3.37 | $6 |
78%
upside
| Market Perform | 2 years ago |
|